Amgen Stock Trades at Premium Despite Promising Repatha Trial Results

Amgen Inc (NASDAQ: AMGN) recently announced promising clinical trial results for its cholesterol-lowering drug Repatha, showing it significantly reduces mortality risk in high-risk patients. The stock is currently trading at a premium of 18.3% above its intrinsic value estimated by GuruFocus' GF Value™ metric.

The Phase 3 VESALIUS-CV trial evaluated Repatha's effect on mortality among over 12,000 high-risk individuals who had not previously suffered heart attacks or strokes. The analysis revealed a 20% reduction in overall mortality after approximately 1.5 years of treatment, with sustained benefits observed over a median follow-up of 4.6 years.

Amgen's dividend yield stands at 2.3%, supported by a payout ratio of 44% and a solid 3-year dividend growth rate of 7.1%. However, the stock price of $432.42 is approximately 18.3% above GuruFocus' intrinsic estimate of $365.50, indicating investors may be paying a premium for these attributes.

The company's GF Score™ stands at a robust 79 out of 100, reflecting strong profitability and growth metrics that underpin its financial health. However, the score also highlights concerns such as a relatively high debt-to-equity ratio and declining margins over recent years.